GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction

Research output: Contribution to journal › Comment/debate › peer-review

ASJC Scopus subject areas

@article{e64798eaad604881937a15287bf3d811,

title = "GSK statement on avodart{\texttrademark} (dutasteride) for prostate cancer risk reduction",

author = "Walsh, {Patrick C.}",

year = "2011",

month = aug,

day = "1",

doi = "10.1016/j.juro.2011.04.053",

language = "English (US)",

volume = "186",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction

AU - Walsh, Patrick C.

PY - 2011/8/1

Y1 - 2011/8/1

UR - http://www.scopus.com/inward/record.url?scp=79960160704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960160704&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.04.053

DO - 10.1016/j.juro.2011.04.053

M3 - Comment/debate

AN - SCOPUS:79960160704

SN - 0022-5347

VL - 186

JO - Journal of Urology

JF - Journal of Urology

IS - 2

ER -